TD Cowen Forecasts Strong Price Appreciation for KindlyMD (NASDAQ:NAKA) Stock

KindlyMD (NASDAQ:NAKA) had its price target boosted by research analysts at TD Cowen from $1.00 to $17.00 in a research report issued on Monday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. TD Cowen’s price target indicates a potential upside of 261.70% from the stock’s current price.

Several other research analysts have also recently issued reports on NAKA. Wall Street Zen raised KindlyMD to a “sell” rating in a research report on Saturday, May 23rd. Weiss Ratings raised shares of KindlyMD from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, May 11th. Finally, Maxim Group decreased their price target on KindlyMD from $60.00 to $30.00 and set a “buy” rating for the company in a research report on Monday, April 6th. Three investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $22.33.

KindlyMD Stock Performance

Shares of NASDAQ NAKA traded down $0.17 during trading on Monday, hitting $4.70. 51,724 shares of the company traded hands, compared to its average volume of 205,498. The business’s fifty day moving average is $4.69 and its 200 day moving average is $8.87. The firm has a market capitalization of $81.78 million, a price-to-earnings ratio of -0.11 and a beta of 16.05. KindlyMD has a fifty-two week low of $3.33 and a fifty-two week high of $659.20.

KindlyMD (NASDAQ:NAKA) last released its quarterly earnings data on Wednesday, May 13th. The company reported ($0.38) EPS for the quarter. KindlyMD had a negative net margin of 7,397.12% and a negative return on equity of 81.32%. The firm had revenue of $2.68 million for the quarter. On average, analysts predict that KindlyMD will post -16.8 EPS for the current year.

Insider Transactions at KindlyMD

In related news, CEO David F. Bailey acquired 55,115 shares of the stock in a transaction dated Thursday, May 28th. The shares were purchased at an average price of $5.62 per share, for a total transaction of $309,746.30. Following the transaction, the chief executive officer owned 3,175,476 shares in the company, valued at $17,846,175.12. This represents a 1.77% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders have purchased 191,448 shares of company stock worth $992,908 in the last three months. Insiders own 24.49% of the company’s stock.

Hedge Funds Weigh In On KindlyMD

A number of large investors have recently added to or reduced their stakes in NAKA. Alyeska Investment Group L.P. purchased a new stake in KindlyMD during the 4th quarter valued at about $8,993,000. ParaFi Capital LP bought a new position in shares of KindlyMD during the third quarter valued at about $443,055,000. Hunting Hill Global Capital LLC bought a new position in KindlyMD during the 4th quarter valued at approximately $4,672,000. Yorkville Advisors Global LP purchased a new position in shares of KindlyMD during the fourth quarter valued at approximately $3,265,000. Finally, UBS Group AG bought a new stake in KindlyMD in the fourth quarter valued at $2,958,000.

KindlyMD Company Profile

Kindly MD, Inc (“KindlyMD” or “Kindly”) is a Utah company formed in 2019. KindlyMD is a healthcare data company, focused on holistic pain management and reducing the impact of the opioid epidemic. KindlyMD offers direct health care to patients integrating prescription medicine and behavioral health services to reduce opioid use in the chronic pain patient population. Kindly believes these methods will help prevent and reduce addiction and dependency on opiates. Our specialty outpatient clinical services are offered on a fee-for-service basis.